Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by canadapieton Feb 04, 2020 9:41am
77 Views
Post# 30639131

RE:RE:RE:RE:RE:RE:RE:Theratechnologies hires Grinspoon for tesamorelin study

RE:RE:RE:RE:RE:RE:RE:Theratechnologies hires Grinspoon for tesamorelin studyThat is something i also noticed and i really don't understand it !!
They are waiting for an answer from the FDA on what they delivered to
them and were confident they had a strong dossier and could answer possible
questions from the FDA....................quote mr. T. !!!!!!???????

And now we read that??............ 

palinc2000 - (2/4/2020 9:22:55 AM) 
RE:RE:RE:RE:RE:RE:Theratechnologies hires Grinspoon for tesamorelin study
I did not say it was a bad development ....on the contrary its long long long overdue imo
However I am a freaking out at this sentence in the PR
 MGH, through Dr. Steven Grinspoon, who is chief of the hospital’s Metabolism Unit, has agreed to assist Theratechnologies in connection with the Study design, selection of optimal patient population, dosing, Study duration and other safety matters 
Study design  dosing etc   etc? Really.In my mind the study design and dosing and study duration  had alreasy been presented to Fda but I guess I was too optimistic!!!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities